Engflag

Sectral 200

Quick links to important sections

Sectral 200

Sectral 200_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sectral 200

Property Description
Active ingredient Acebutolol Hydrochloride (Acebutolol)
Form Oral Dosage Form (Tablet/Capsule)
Pharmacological class Beta-Adrenergic Blocking Agent (β-Blocker)
General purpose Cardiovascular agent to stabilize heart function
Origin Synthetic compound

Sectral 200 is a prescription-only medication whose active component is Acebutolol Hydrochloride (Acebutolol), a synthetic substance belonging to the pharmacological class of beta-adrenergic blocking agents, commonly known as beta-blockers. As a cardiovascular agent, its general purpose is to help stabilize heart function and manage pressure within the circulatory system. This classification places it among drugs used to modulate the body's response to stress signals like adrenaline.

What Kind of Beta-Blocker is Acebutolol?

Acebutolol is defined as a cardioselective beta1 selective blocker that possesses a unique feature called Intrinsic Sympathomimetic Activity (ISA). This classification means the drug predominantly targets the beta-1 receptors found mainly in the heart, offering a more focused action compared to non-selective beta-blockers. The ISA characteristic means Acebutolol provides a mild, stabilizing stimulation to the heart receptors while simultaneously preventing overwhelming effects from stress hormones, distinguishing its action from agents that solely block receptor activity. Selective beta-blockers are utilized to assist the heart in reducing its overall workload. A typical use scenario involves helping the heart maintain a consistent, regulated rhythm.

Composition, Origin, and Administration Type

Sectral 200 is a synthetic, single-ingredient compound typically formulated as an oral dosage form, specifically a tablet or capsule, designed for systemic absorption. The composition includes the active ingredient, Acebutolol Hydrochloride, combined with necessary solid excipients (inert base materials). The oral route of administration confirms that the medication is swallowed to allow the active ingredient to enter the bloodstream and travel throughout the body to reach its primary target receptors in the cardiovascular system.

Regulatory References

  1. NIH/NLM information on Acebutolol

What side effects are possible with Sectral 200?

Official Safety Profile and Adverse Reactions

The safety profile for Sectral 200 (acebutolol) is officially documented by government regulatory bodies, detailing potential physiological effects and safety constraints. Adverse reactions are formally classified by frequency and the body systems they involve.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their likelihood, according to established regulatory standards:

  • Common: Reactions affecting 1 to 10 users in 100, including fatigue, dizziness, headache, nausea, and dyspepsia (indigestion).
  • Uncommon/Infrequent: Less common events such as bradycardia (slow heart rate), hypotension (low blood pressure), insomnia, depression, diarrhea, constipation, rash, and impotence.
  • Rare: Infrequently observed but serious reactions, including bronchospasm, Lupus-like syndrome, and the Oculomucocutaneous syndrome.

System-Organ Class and Serious Reactions

Side effects are grouped by the physiological system affected, which formally includes Cardiac, Vascular, Nervous System, Psychiatric, and Gastrointestinal Disorders. The regulatory documents explicitly note the potential for serious adverse reactions, such as severe worsening of heart failure and severe bradycardia, particularly in patients with pre-existing cardiac disease.

Population-Specific and Duration-Related Safety

Specific safety considerations are defined for certain patient groups. Individuals with renal impairment have reduced clearance of the drug, which can increase the risk of accumulation. Patients with diabetes mellitus require careful monitoring as the medication may mask certain signs of hypoglycemia. Furthermore, the official label includes a safety note concerning the risk of a Withdrawal Syndrome; the abrupt cessation of therapy, especially in patients with coronary artery disease, is documented as potentially leading to serious cardiac events.

Overdose and Emergency Response

Overdose Manifestations and Required Emergency Action

Official regulatory documents state that overdosage with Sectral 200 (Acebutolol) may result in severe manifestations stemming from profound beta-blockade. Documented clinical signs include bradycardia (abnormally slow heart rate), hypotension (low blood pressure), and related effects such as dizziness or fainting. Other reported overdose presentations are fatigue, weakness, swelling of the extremities, and difficulty breathing or wheezing.

Immediate medical attention is mandated if overdosage is suspected. Urgent medical services must be contacted if the individual exhibits life-threatening outcomes such as seizures, sudden collapse, or profound trouble breathing, as these indicate a severe emergency. Calling the Poison Control helpline is also required as an immediate action.

Official Overdose Management

Management outlined in regulatory prescribing information is strictly supportive and symptomatic. Initial steps may include gastric evacuation procedures, such as emesis or gastric lavage. To address severe bradycardia, treatment may involve intravenous administration of atropine, followed by isoproterenol if the heart rate remains inadequate. For persistent hypotension, vasopressors (such as epinephrine or dobutamine) are administered, necessitating frequent monitoring of blood pressure and pulse rate. Bronchospasm, if present, is managed with a theophylline derivative or a parenteral beta2-stimulant.

Therapeutic Uses of Sectral 200

Sectral 200: Main Therapeutic Uses and Patient Benefits

Sectral 200 (acebutolol) is a prescription medication used in the management of specific conditions linked to the heart and circulatory system, and is considered relevant across conditions characterized by periods of heightened symptoms. It is applied across domains where additional symptomatic support is needed.

Supporting Symptoms that Intensify or Fluctuuate

This medication is relevant in clinical settings marked by episodic or fluctuating manifestations, such as conditions characterized by periods of heightened symptoms. It helps address symptom clusters that may become intense or disruptive, offering symptomatic relief that assists patients with coping more steadily with symptom fluctuations.

Managing Noticeable Interference with Daily Stability

Sectral is commonly used to help with conditions where symptoms may intensify temporarily, such as those presenting with systemic or localized discomfort. The medication plays a role in assisting with maintaining functional stability, contributing to improved comfort during periods of heightened symptoms, and supporting general well-being during symptomatic phases.

Temporary Assistance for Heightened Discomfort

The medicine is relevant in contexts involving heightened systemic burden, particularly when symptoms create noticeable functional strain. It is applied during phases of increased distress or discomfort. It supports the patient during difficult episodes by easing distress, helping to ease the overall symptom load when symptoms become more noticeable.

Quick Fact: Used in areas where short-term symptom management is appropriate for symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

Absolute Contraindications

Sectral 200 (acebutolol) is strictly contraindicated and must not be used in populations presenting with specific severe cardiac or allergic conditions, as documented in official regulatory labeling:

  • Persistently Severe Bradycardia (pathologically slow heart rate).
  • Second- or Third-Degree Heart Block (disturbances in heart conduction).
  • Overt Cardiac Failure (uncompensated heart failure) or Cardiogenic Shock.
  • Known Hypersensitivity or allergy to acebutolol or any formulation component.

Age and Developmental Restrictions

Population Eligibility Status (Regulatory Wording)
Pediatric (Children/Adolescents) Safety and efficacy have not been established. Use is not permitted under standard labeled conditions.
Adults Established as the approved population for its labeled use.
Older Adults (Geriatric) Generally acceptable, but lower doses may be required due to possible age-related decreases in liver or kidney function.

Conditional Use and Comorbidity Limitations

Use is restricted or requires special caution in the following populations:

  • Impaired Renal Function: A reduction in dosage is required—specifically, a 50% to 75% reduction—due to the primary elimination route of the active metabolite.
  • Pregnancy: Use is permitted only if the potential benefit justifies the potential risk to the fetus.
  • Lactation (Breastfeeding): Use is not recommended as the drug and its active metabolite are excreted into breast milk.
  • Bronchospastic Disease: Use requires caution at low doses if alternative treatments fail.
  • Diabetes/Hyperthyroidism: Use requires caution as the medication may mask symptoms of acute events like hypoglycemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acebutolol's interaction profile is defined by potential pharmacodynamic reinforcement with other cardiovascular agents and by exposure modification in specific patient populations, as documented in official prescribing information.

Contraindicated and High-Risk Combinations

Co-administration with Verapamil, Floctafenine, or Sultopride is formally classified as contraindicated by some regulatory authorities due to severe risks, including disorders of automatism, cardiac conduction failure, or reduced cardiovascular compensation. The use of alpha-adrenergic stimulants (e.g., in some nasal drops or cold remedies) must be avoided due to the documented risk of severe hypertensive reactions.

Clinically Significant Interactions

  • Pharmacodynamic Reinforcement: Co-administration with Digitalis glycosides (e.g., Digoxin) or Reserpine carries a risk of marked bradycardia or hypotension due to additive effects on heart rate and conduction.
  • Antagonistic Effects: Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are documented to potentially blunt the antihypertensive effect of the medicine.
  • Masking of Symptoms: When used with hypoglycemic agents (e.g., Insulin), Acebutolol may mask the physical signs of hypoglycemia, specifically tachycardia.

Exposure and Population-Specific Constraints

  • Renal Impairment: The daily dose must be reduced by 50% or 75% based on creatinine clearance, as the active metabolite, diacetolol, is eliminated predominantly by the kidneys.
  • Geriatric Population: The bioavailability of the medicine and its metabolite is approximately doubled in this population.

No significant pharmacokinetic influence is documented between Acebutolol and specific agents like Warfarin or Tolbutamide.

Mechanism of Action

Sectral 200, containing acebutolol, functions primarily as a cardioselective beta1-adrenergic receptor antagonist with intrinsic sympathomimetic activity (ISA).

Acebutolol and its active metabolite, diacetolol, preferentially target and bind to beta1-adrenergic receptors, which are highly expressed in cardiac tissue, functioning as competitive inhibitors of the endogenous catecholamines, epinephrine and norepinephrine. This receptor blockade prevents activation of the coupled Gs protein, thereby inhibiting the downstream adenylyl cyclase enzyme. This, in turn, reduces the intracellular concentration of cyclic adenosine monophosphate (cAMP), leading to decreased activity of cAMP-dependent protein kinase (PKA).

Simultaneously, the partial agonist nature (ISA) of acebutolol provides a low-level agonism at the beta1-receptors, maintaining a minimal degree of sympathetic tone. The net consequence of the beta1-receptor antagonism is a reduction in chronotropy (heart rate) and inotropy (contractility) in the heart. System-level physiological modulation includes a decrease in cardiac output and the suppression of ectopic pacemaker activity.

Dosage and Administration Information

How to Use Sectral 200 (Acebutolol)

This section describes the administration for Sectral (acebutolol).

Acebutolol is for oral administration, typically available as 200 mg and 400 mg capsules. The capsule must be swallowed whole with water and should not be crushed or chewed. Administration is generally independent of meal timing.

Official Dosing and Frequency

A common approach involves starting at a prescribed initial dose and adjusting based on the clinical scenario. For hypertension, the usual starting dose is 400 mg daily, which may be given as a single daily dose or in two divided doses. Maintenance doses typically range between 400 mg and 800 mg daily, with a maximum dose of 1200 mg in divided doses. For ventricular arrhythmias, the initial dose is 400 mg daily, given as 200 mg twice daily, with maintenance doses ranging from 600 mg to 1200 mg daily. If a dose is missed, it should be taken as soon as it is remembered, unless it is close to the next scheduled dose, in which case the missed dose should be skipped to avoid a double dose.

Specific Population Adjustments

Certain patient populations may require dose adjustments:

  • Renal Impairment: The daily dose is reduced by 50% when creatinine clearance (CrCl) is 25-50 mL/min and by 75% when CrCl is less than 25 mL/min.
  • Older Adults: Doses exceeding 800 mg daily should generally be avoided due to the potential for increased bioavailability.

If the medication needs to be discontinued, the dosage must be reduced gradually over a period of approximately two weeks.

Recent Clinical Evidence

Sectral 200: Recent Clinical Evidence

This section summarizes clinical evidence related to Sectral 200 (Acebutolol) for its approved indications, including hypertension and specific cardiac arrhythmias.

Efficacy in Hypertension

Clinical trials have established Acebutolol's role as a beta-blocker that may be used in the management of mild-to-moderate hypertension. Research suggests that administration of Acebutolol is associated with a reduction in both systolic and diastolic blood pressure in adult patient populations. The anti-hypertensive effect is often attributed to the drug's activity in reducing heart rate and cardiac output. Long-term studies evaluating cardiovascular outcomes in patients receiving Acebutolol treatment have been conducted as part of the evidence base for its use in chronic blood pressure control.

Use in Cardiac Arrhythmias

Acebutolol is indicated for the management of ventricular premature beats (VPBs). Studies have investigated the drug's effect on suppressing the frequency of these ectopic beats, particularly following myocardial infarction. The evidence base includes trials that have evaluated the drug's ability to stabilize cardiac rhythm through its electrophysiological properties. Acebutolol's cardioselectivity and intrinsic sympathomimetic activity (ISA) are factors studied in relation to its profile in treating these specific cardiac rhythm disturbances.

Comparative Trial Data Overview

Research has compared Acebutolol to other beta-blockers and placebo across various trial settings. A key aspect of these trials involves assessing the effects on exercise tolerance and quality of life measures, which are relevant to patients with hypertension and chronic stable angina.

Indication Studied Primary Outcome Measured Trial Setting
Hypertension Change in resting blood pressure (SBP/DBP) Randomized Controlled Trials (RCTs)
Arrhythmia (VPBs) Reduction in ectopic beat count (24-hour Holter) Crossover and Comparative Studies

Acebutolol's clinical profile is considered distinct among beta-blockers due to its partial agonist activity (ISA), a feature that has been evaluated for its potential influence on resting heart rate and lipid metabolism markers.

Frequently Asked Questions (FAQ)

Common questions about Sectral 200 (FAQ)

Q: What is Sectral 200?

A: Sectral 200 (acebutolol hydrochloride) is a medication classified as a beta-blocker (specifically, a cardioselective beta-adrenoreceptor blocking agent).

It works by affecting the body's response to certain nerve impulses, especially in the heart. This action helps to slow the heart rate and reduce blood pressure. It also has anti-arrhythmic properties.

Q: What is Sectral 200 used to treat?

A: Sectral 200 is approved for the management of:

  • High blood pressure (hypertension), often used in combination with other medications like diuretics.
  • Angina pectoris (chest pain caused by reduced blood flow to the heart).
  • Certain types of heart rhythm disorders (ventricular arrhythmias).

Q: How should I take Sectral 200?

A: Sectral 200 is an oral medication that should be taken exactly as prescribed by your healthcare provider. The tablets are typically swallowed whole with water. It is generally recommended to take the medication with food and at a consistent time each day.

Q: What should I do if I miss a dose of Sectral 200?

A: If you forget to take a dose, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose.

Q: Can I stop taking Sectral 200 if I feel better?

A: No, you should never stop taking Sectral 200 suddenly or change your dose without first consulting your healthcare provider. Abrupt discontinuation of beta-blockers, including Sectral, can lead to serious health issues, particularly an exacerbation of chest pain or heart rhythm problems. If the medication needs to be stopped, your doctor will usually advise a gradual dose reduction over a period of about two weeks.

Q: What are the common side effects of Sectral 200?

A: Common side effects may include:

  • Fatigue
  • Dizziness
  • Nausea
  • Shortness of breath (dyspnea)

Contact your healthcare provider if any side effects are severe or persistent.

Q: Who should not take Sectral 200?

A: Sectral 200 is contraindicated and should generally not be used in individuals with certain heart conditions, including:

  • Persistently severe slow heart rate (bradycardia).
  • Second or third-degree heart block (without a pacemaker).
  • Overt heart failure.
  • Cardiogenic shock.

It is also generally advised to avoid beta-blockers in patients with severe bronchospastic diseases, such as severe asthma or severe Chronic Obstructive Pulmonary Disease (COPD). Your doctor must consider your complete medical history before prescribing Sectral 200.

How should Sectral 200 be stored and disposed of?

Storage Requirements

Sectral (acebutolol hydrochloride) 200 mg capsules must be stored at Controlled Room Temperature, which is generally 20 C to 25 C (68 F to 77 F). The product should be protected from specific environmental conditions.

Storage Condition Requirement
Temperature Controlled Room Temperature (20 C to 25 C)
Protection Keep away from heat, moisture, and direct light
Container Store in a closed container, often kept tightly closed
Child Safety Mandatory to keep out of the reach of children

Disposal Instructions

The medicine should not be kept if it is outdated or no longer needed. Disposal of unused or expired Sectral 200 capsules must be completed according to local regulations. Patients are advised to consult a healthcare professional regarding the appropriate method for discarding the unused product, aligning with government-approved guidelines for safe pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sectral 200 found in:

A-Z Index: